Saturday 7 February 2026

One To Watch

Clasp Therapeutics

A biotechnology company developing immuno-oncology treatments using next-generation T cell engagers (TCEs)

Company Overview

Want to Update your Company's Profile?


Latest Clasp Therapeutics News

Johns Hopkins research reels in $150 million from top tier investors
21 March 2024
More Clasp Therapeutics news >


Today's issue

Health Canada approves Livmarli for PFIC and ALGS
Pharmaceutical
Health Canada approves Livmarli for PFIC and ALGS
7 February 2026
Biotechnology
Novartis breaks ground on San Diego biomedical research center
7 February 2026
article
Eikon’s IPO splash fades as shares tumble on debut
6 February 2026
Biotechnology
Kelun-Biotech expands label in China breast cancer market
6 February 2026
Biotechnology
FDA grants priority review for Hympavzi sBLA
6 February 2026
Biotechnology
Biogen 4th-quarter 2025 results beat forecasts
6 February 2026
Biotechnology
Idorsia progresses lucerastat as a potential oral therapy for Fabry disease
6 February 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze